Ultrasound has been established as a baseline imaging technique for thyroid nodules. The main advantage of adding CEUS is the ability to assess the sequence and intensity of vascular perfusion and hemodynamics in the thyroid nodule, thus providing real-time characterization of nodule features, considered a valuable new approach in the determination of benign vs. malignant nodules. Original studies, reviews and six meta-analyses were included in this article. A total of 624 studies were retrieved, and 107 were included in the study. As recognized for thyroid nodule malignancy risk stratification by US, for acceptable accuracy in malignancy a combination of several CEUS parameters should be applied: hypo-enhancement, heterogeneous, peripheral irregular enhancement in combination with internal enhancement patterns, and slow wash-in and wash-out curve lower than in normal thyroid tissue. In contrast, homogeneous, intense enhancement with smooth rim enhancement and “fast-in and slow-out” are indicative of the benignity of the thyroid nodule. Even though overlapping features require standardization, with further research, CEUS may achieve reliable performance in detecting or excluding thyroid cancer. It can also play an operative role in guiding ablation procedures of benign and malignant thyroid nodules and metastatic lymph nodes, and providing accurate follow-up imaging to assess treatment efficacy.

Objectives: This study aimed to define patterns of liver injury after severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) infection using multiparametric ultrasound (mpUS) in a variable patient population with differing severities of COVID‐19.Methods: Ninety patients were enrolled into the study: 56 had SARS‐CoV‐2 3–9 months prior to enrolment; 34 served as a clinically healthy control group. All patients underwent an mpUS evaluation of the liver (elastography, dispersion and attenuation imaging). Seventy‐six patients had abdominal magnetic resonance (MR) and noncontrast enhanced thoracic computed tomography (CT) scans performed at the same day. All patients were screened for biochemical markers of liver injury.Results: Liver elasticity, viscosity, and steatosis values were significantly altered in patients after COVID‐19, with particularly higher fibrosis scores compared to the control group (P < .001). Increased biochemical markers of liver injury correlated with changes in mpUS (P < .05), but not with findings on CT or MR findings. Seventeen of 34 hospitalized patients had a moderate or severe course of the disease course with more pronounced changes in mpUS. Increased body mass index was found to influence liver injury and correlated with more severe forms of COVID‐19 (P < .001).Conclusions: COVID‐19 can cause liver injury observable using mpUS. More severe forms of COVID‐19 and patient obesity are related to increased values of liver damage observed. In comparison to MRI and CT, mpUS appears to be more sensitive to involvement of liver parenchyma. Further research is warranted to establish this promising method for evaluating post‐COVID‐19 liver involvement in the aftermath of the pandemic.

Background: Liver damage in COVID-19 is multifaceted, including liver steatosis and inflammation. Multiparametric ultrasound (mpUS) is an imaging modality that has the capacity to evaluate various facets of overall liver health and is relatively accessible and thus is an excellent choice to determine parenchymal changes. Methods: A longitudinal prospective study was designed to evaluate long-term hepatic damage following COVID-19 using mpUS. Patients were assessed within a 3–6-month period after the initial episode of COVID-19 and subsequently had a follow-up after 3 years compared to a control group. Liver stiffness (2D-SWE), attenuation (ATI), and shear wave dispersion (SWD) were measured to quantify liver stiffness, steatosis, and tissue viscosity. Results: A total of 129 patients were scanned at the baseline assessment, 90 patients in research group (58 patients had a follow-up) and 39 as a clinically healthy control group, and all were included in the follow-up for evaluation after 3 years. The mpUS evaluation in research group revealed a median SWE decrease from 5.04 ± 1.74 kPa to 4.59 ± 0.81 kPa and SWD decrease from 11.88 ± 1.73 m/s/kHz to 10.83 ± 1.49 m/s/kHz (p > 0.05); in contrast, median ATI values showed slight increase over time—0.56 ± 0.09 dB/cm/MHz to 0.60 ± 0.09 dB/cm/MHz (p > 0.05). Control group was stratified according to subsequent COVID-19 status. In both the COVID-negative and -positive subgroups SWE slightly increased from initial 4.55 ± 0.78 kPa to 4.8 ± 0.88 kPa and 4.7 ± 1.29 kPa, median SWD had a slight decrease from initial 10.80 ± 1.73 m/s/kHz to 10.15 ± 1.87 m/s/kHz and 10.6 ± 1.82 m/s/kHz (p > 0.05), and ATI increased significantly from initial 0.57 ± 0.08 dB/cm/MHz to 0.62 ± 0.09 dB/cm/MHz and 0.65 ± 0.07 dB/cm/MHz (p < 0.05), respectively. Conclusions: The study found that initially COVID-19-affected patients showed stable ATI and BMI values, no hepatic steatosis, normal SWE, and reduced dispersion which suggests resolving inflammation without fibrosis. Controls showed increased ATI and mild steatosis, likely linked to BMI and metabolic changes rather than direct viral liver injury.